[Present status and future prospects of anti-allergic drugs].
Hiroichi
H
Nagai
D018926:Anti-Allergic Agents; D004205:Cromolyn Sodium; D016207:Cytokines / Q000037:antagonists & inhibitors; D004304:Dosage Forms; D015195:Drug Design; D005938:Glucocorticoids; D006633:Histamine Antagonists; D006801:Humans; D006967:Hypersensitivity / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy*; D020024:Leukotriene Antagonists; D008407:Mast Cells; D017410:Practice Guidelines as Topic; D018417:Th1 Cells / Q000276:immunology; D018418:Th2 Cells / Q000276:immunology; D013928:Thromboxane A2 / Q000037:antagonists & inhibitors
D018926:Anti-Allergic Agents; D016207:Cytokines; D004304:Dosage Forms; D005938:Glucocorticoids; D006633:Histamine Antagonists; D020024:Leukotriene Antagonists; D013928:Thromboxane A2; D004205:Cromolyn Sodium